Sign up to save your podcasts
Or
Share Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center.
In this episode, we covered:
• The importance of shared decision-making in CLL treatment.
• When to initiate treatment for newly diagnosed CLL patients.
• The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors.
• Key considerations in choosing the right BTK inhibitor and managing side effects.
• The relevance of minimal residual disease (MRD) in treatment duration.
• Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice.
Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib
View all episodes
By Oncology Brothers
4.8
4040 ratings
Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center.
In this episode, we covered:
• The importance of shared decision-making in CLL treatment.
• When to initiate treatment for newly diagnosed CLL patients.
• The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors.
• Key considerations in choosing the right BTK inhibitor and managing side effects.
• The relevance of minimal residual disease (MRD) in treatment duration.
• Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice.
Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,358 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners